Table 3.
Factors Associated with the Outcome (Recovered vs. Fatal/Not Recovered*) Among Patients with Reported Adverse Drug Events Suspected to be Caused by Tocilizumab Used in the Treatment of COVID-19 in the World Health Organization (WHO) Database (n = 261)
| Variables |
Simple Logistic Regression |
Multiple Logistic Regression |
||
|---|---|---|---|---|
| Odds ratio (95% CIb) | p-value | Odds ratio (95% CIb) | p-value | |
| Sex: | ||||
| Male* | 0 | 1.000 | 0 | 1.000 |
| Female | 1.096 (0.653, 1.839) | 0.729 | 1.217 (0.652, 2.268) | 0.538 |
| Age Group (years): | ||||
| < 45* | 0 | 1.000 | 0 | 1.000 |
| 45–64 | 0.879 (0.436, 1.773) | 0.718 | 0.642 (0.277, 1.485) | 0.300 |
| > 64 | 0.617 (0.304, 1.255) | 0.183 | 0.363 (0.153, 0.862) | 0.022 |
| WHO Region: | ||||
| Americas* | 0 | 1.000 | 0 | 1.000 |
| Europe | 1.440 (0.922. 2.248) | 0.109 | 3.716 (2.018, 6.844) | < 0.001 |
| Other regions | 0.991 (0.561, 1.753) | 0.976 | 0.964 (0.397, 2.493) | 0.887 |
aControlled for the confounding effect. b Confidence interval. * The reference group.